Fig. 1 · Structure

Documents & Downloads

NBQX (FG9202)

Cat. No. A13109 CAS 118876-58-7

AMPA Receptor Antagonist

NBQX is a potent, selective and competitive AMPA receptor antagonist.

In Stock

Publications for NBQX

1 publication citing this product

  1. Huang Li, .et al. , Physiol Behav, 2024, Apr 1:277:114461 PMID: 38215863

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

NBQX competitively antagonized AMPA-evoked plateau currents in cultured rat cortical neurons (reported pKi 6.6). This functional estimate is specific to the neuronal assay. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 135 μM Antagonist activity at human recombinant GLUK6/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 2.5 μM Antagonist activity at human recombinant GLUA2-AMPA receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 28 μM Antagonist activity at human recombinant GLUK5/GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 28 μM Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK6 by FLIPR assay [PMID: 16610801]
HEK293 IC50 29 μM Antagonist activity at human recombinant GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 37 μM Antagonist activity at human recombinant GLUK5 receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 37 μM Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5 by FLIPR assay [PMID: 16610801]
HEK293 IC50 50 μM Antagonist activity at human recombinant GLUK5/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay [PMID: 17348638]
HEK293 IC50 50 μM Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK2 by FLIPR assay [PMID: 16610801]
HEK293 IC50 74 μM Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay [PMID: 19819046]
Neuron IC50 11.9 μM Inhibition of kainate-induced C57BL/6N mouse hippocampal neurons excitotoxicity after 48 hrs by MTT assay [PMID: 18083036]
Oocyte IC50 31 nM Antagonistic activity against Ionotropic glutamate receptor AMPA using kainate-evoked current in Xenopus oocytes injected with rat brain mRNA [PMID: 11133083]
Oocyte IC50 31 nM Inhibitory activity against generation of currents by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA [PMID: 10843235]

13 records · Scroll to view more

In Vitro Studies

NBQX responses depended on cell type and current phase: 0.3 μM suppressed peak AMPA currents in cortical and spinal cord neurons, but enhanced spinal cord plateau currents. Higher concentrations suppressed the spinal plateau response. NBQX also reduced currents after cyclothiazide potentiation, supporting a contribution from desensitization. [1]

AMPA-current antagonism and context-dependent potentiation

Cell-based study · Primary cortical and spinal cord neurons from Wistar rat embryos; recordings 7–14 days after plating. [1]

NBQX inhibited peak AMPA currents in both preparations, but enhanced spinal cord plateau currents at low antagonist concentrations. Cortical concentration-response shifts supported competitive antagonism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQXCurrent reduction 62±7.5%; mean±s.e.mean; n=7 neurons; P<0.001 versus control[1]
Reduction of plateau current evoked by 100 μM AMPA with 0.3 μM NBQXCurrent reduction 42±9.6%; mean±s.e.mean; n=7 neurons; P<0.001 versus control[1]
Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQXCurrent reduction 34±3%; mean±s.e.mean; n=20 neurons; P<0.001 versus control[1]
Spinal cord plateau current with 100 μM AMPA and 0.3 μM NBQXPercentage of control current 117±4%; mean±s.e.mean; n=20 neurons; P<0.001 versus control[1]
Competitive antagonism of cortical AMPA plateau responsespKi; Schild slope pKi=6.6; slope=0.92[1]
Spinal cord plateau-current response to 500 μM AMPA across NBQX concentrationsConcentration-dependent effect Potentiation at 0.1–1 μM NBQX; maximum increase 40±7% at 1 μM (n=7; P<0.001); depression significant versus control at ≥2.5 μM (P<0.05).[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3 μM NBQX with 100 μM AMPA (Figure 1); 0.1 and 0.3 μM NBQX in cortical AMPA concentration-response analysis (Figure 2A); 0.1–3 μM NBQX with 500 μM AMPA (Figure 2C).
Exposure duration
Figure 1: 5 s NBQX pretreatment, then 15 s AMPA application with NBQX continuously present; 40 s between agonist applications.
Method
Whole-cell patch clamp at −60 mV and room temperature (20–24°C); semi-rapid compound application.
Vehicle
NBQX stock in artificial balanced salt solution (ABSS); AMPA stock in 50 mM NaOH, diluted for recording.
Co-treatment
AMPA challenge; 0.2 μM tetrodotoxin in recording medium to suppress regenerative sodium currents and synaptic potentials.
Reported limits
NBQX salt/hydration state, lot and purity not specified; no separately reported vehicle-only response in the selected experiment. Figure 1 application duration is not assigned to every Figure 2 condition.
Methods and source locations

Compound reported in the paper: NBQX; Compound label in the paper: NBQX, gift from Novo Nordisk

Results apply to the authors’ reported NBQX preparation and stated model. No salt conversion, Adooq provenance or lot-level performance claim.

Results, Responses mediated by AMPA receptors; Figures 1A–C and 2A–C and captions; Methods, Cell culture, Electrophysiological recordings, application of compounds, Data analysis

Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX: Current normalized to the AMPA response without NBQX; two-tailed t-test. — Results, first AMPA-response paragraph; Figure 1A,C and caption

Reduction of plateau current evoked by 100 μM AMPA with 0.3 μM NBQX: Whole-cell recording; control is AMPA without NBQX. — Results, first AMPA-response paragraph; Figure 1A,C and caption

Reduction of peak current evoked by 100 μM AMPA with 0.3 μM NBQX: Whole-cell recording; control is AMPA without NBQX. — Results, first AMPA-response paragraph; Figure 1B,C and caption

Spinal cord plateau current with 100 μM AMPA and 0.3 μM NBQX: Normalized to the AMPA-alone plateau current; this is enhancement to 117%, not a 117% increase. — Results, first AMPA-response paragraph; Figure 1B,C and caption

Competitive antagonism of cortical AMPA plateau responses: Parallel rightward concentration-response shifts at 0.1 and 0.3 μM NBQX; functional Schild analysis, not radioligand binding IC50. — Results, AMPA concentration-response paragraph; Figure 2A caption

Spinal cord plateau-current response to 500 μM AMPA across NBQX concentrations: Mean±s.e.mean; normalized to 500 μM AMPA alone. Cortical responses were depressed over the same antagonist range without potentiation. — Results, end of AMPA concentration-response paragraph; Figure 2C and caption

Desensitization-blockade control for spinal cord plateau responses

Cell-based study · Cultured Wistar rat spinal cord neurons; whole-cell AMPA-current recordings. [1]

After cyclothiazide increased sustained AMPA responses, NBQX reduced the potentiated current. This supports the authors’ interpretation that desensitization contributes to the low-concentration plateau enhancement; it does not establish subunit-specific causation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spinal cord AMPA plateau currents after CTZ and after addition of NBQXDirection of current change NBQX reduced the CTZ-potentiated plateau current.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3 μM NBQX with 100 μM AMPA and 100 μM cyclothiazide (CTZ).
Exposure duration
Figure 5 refers to Figure 4B application: CTZ pretreatment for 30 s before co-application with AMPA. A separate AMPA pulse duration and NBQX pretreatment duration are not specified in those captions.
Method
Whole-cell patch clamp; compare AMPA alone, AMPA plus CTZ, and AMPA plus CTZ plus NBQX.
Vehicle
NBQX stock in ABSS; CTZ stock in DMSO; AMPA stock in 50 mM NaOH, diluted for recording.
Co-treatment
CTZ desensitization-blockade control with AMPA challenge; effects are not NBQX monotherapy responses.
Reported limits
Final DMSO concentration, NBQX solid form and purity not specified. CTZ-alone neuron count differs between Results prose (six) and Figure 5B (eight); the NBQX bar is labeled six. No exact count-dependent effect estimate adopted.
Methods and source locations

Compound reported in the paper: NBQX; Compound label in the paper: NBQX, gift from Novo Nordisk

Results apply to the authors’ reported NBQX preparation and stated model. No salt conversion, Adooq provenance or lot-level performance claim.

Results, effect of NBQX following blockade of desensitization by CTZ; Figure 5A–B and caption; Figure 4B caption (application timing); Methods, electrophysiology and compound application

Spinal cord AMPA plateau currents after CTZ and after addition of NBQX: AMPA-alone, AMPA plus CTZ and AMPA plus CTZ plus NBQX responses compared. Figure 5 traces and bars viewed; no numeric estimate inferred from the image. — Results, CTZ/NBQX paragraph; Figure 5A–B and caption

In Vivo Studies

In male C57BL/6J mice, NBQX alone (15 or 30 mg/kg, intraperitoneal) did not significantly change contextual fear conditioning. Combined with mecamylamine (1 mg/kg), both doses reduced contextual freezing; cued freezing showed no significant overall drug effect. These findings distinguish single-agent from combination responses. [2]

Single-agent and combined NBQX effects on fear conditioning

Animal study · Male C57BL/6J mice, 8–16 weeks old; n=7–9 per main group; separate no-shock control groups n=4 each. [2]

NBQX alone did not significantly alter contextual or cued fear conditioning at the tested doses. Combining NBQX with mecamylamine reduced contextual freezing, while the overall cued-freezing comparison was not significant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Contextual freezing approximately 24 h after trainingANOVA and post-hoc comparisons F(5,41)=5.01, P<0.01; both NBQX/mecamylamine combinations differed from saline (P<0.05); NBQX alone did not significantly differ from saline.[2]
Cued freezing during the auditory conditioned stimulusANOVA F(5,41)=1.99, P>0.05[2]
Baseline freezing and generalized pre-CS freezing; no-shock associative controlControl comparisons Baseline: F(5,41)=0.51, P>0.05; pre-CS: F(5,41)=2.32, P>0.05. No-shock saline versus combination: no differences in baseline, context or CS freezing (all P>0.05).[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
One training-day administration of each indicated active drug.
Vehicle
0.9% physiological saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NBQX alone, 15 mg/kg
15 mg/kg
Saline; NBQX-alone and mecamylamine-alone groups included in combination comparisons. Baseline, pre-CS and separate no-shock controls also examined.No significant difference in contextual freezing versus saline; no significant overall drug effect on cued freezing.[2]
NBQX alone, 30 mg/kg
30 mg/kg
Saline; NBQX-alone and mecamylamine-alone groups included in combination comparisons. Baseline, pre-CS and separate no-shock controls also examined.No significant difference in contextual freezing versus saline; no significant overall drug effect on cued freezing.[2]
NBQX 15 mg/kg plus mecamylamine
15 mg/kg NBQX plus 1 mg/kg mecamylamine
Saline; NBQX-alone and mecamylamine-alone groups included in combination comparisons. Baseline, pre-CS and separate no-shock controls also examined.Contextual freezing reduced versus saline and either drug alone (P<0.05); no significant overall cued-freezing effect.[2]
NBQX 30 mg/kg plus mecamylamine
30 mg/kg NBQX plus 1 mg/kg mecamylamine
Saline; NBQX-alone and mecamylamine-alone groups included in combination comparisons. Baseline, pre-CS and separate no-shock controls also examined.Contextual freezing reduced versus saline and either drug alone (P<0.05); no significant overall cued-freezing effect.[2]
NBQX alone, 15 mg/kg
Model: Male C57BL/6J mice, 8–16 weeks old; n=7–9 per main group; separate no-shock control groups n=4 each.
Treatment course: NBQX 30 min before training.
Reported limits: NBQX salt, lot/purity and dose mass basis not specified. The acquired Subjects section gives group-size range rather than exact main-group allocation; no exact freezing means are transcribed from bars.
NBQX alone, 30 mg/kg
Model: Male C57BL/6J mice, 8–16 weeks old; n=7–9 per main group; separate no-shock control groups n=4 each.
Treatment course: NBQX 30 min before training.
Reported limits: NBQX salt, lot/purity and dose mass basis not specified. The acquired Subjects section gives group-size range rather than exact main-group allocation; no exact freezing means are transcribed from bars.
NBQX 15 mg/kg plus mecamylamine
Model: Male C57BL/6J mice, 8–16 weeks old; n=7–9 per main group; separate no-shock control groups n=4 each.
Treatment course: NBQX 30 min before training; mecamylamine 15 min before training.
Reported limits: NBQX salt, lot/purity and dose mass basis not specified. The acquired Subjects section gives group-size range rather than exact main-group allocation; no exact freezing means are transcribed from bars.
NBQX 30 mg/kg plus mecamylamine
Model: Male C57BL/6J mice, 8–16 weeks old; n=7–9 per main group; separate no-shock control groups n=4 each.
Treatment course: NBQX 30 min before training; mecamylamine 15 min before training.
Reported limits: NBQX salt, lot/purity and dose mass basis not specified. The acquired Subjects section gives group-size range rather than exact main-group allocation; no exact freezing means are transcribed from bars.
Methods and source locations

Compound reported in the paper: NBQX; Compound label in the paper: NBQX from Sigma Co.

Results apply to the authors’ reported NBQX preparation and stated model. No salt conversion, Adooq provenance or lot-level performance claim.

Results, Experiment 3: AMPA/nAChR interactions in fear conditioning, Figures 3–4 and captions; Materials and Methods, Subjects, Behavioral procedures: Fear conditioning, Drugs, Statistical analysis

Contextual freezing approximately 24 h after training: One-way ANOVA; Tukey HSD post-hoc. Figure 3 caption also identifies combination differences versus either drug alone. — Results, Experiment 3; Figure 3 and caption; Statistical analysis

Cued freezing during the auditory conditioned stimulus: Same fear-conditioning experiment, altered-context cued test. Failure to detect a difference is not proof of equivalence. — Results, Experiment 3; Figure 4 and caption

Baseline freezing and generalized pre-CS freezing; no-shock associative control: Separate no-shock control (n=4/group) supports the associative interpretation; no-shock results are reported as data not shown. — Results, Experiment 3, baseline/pre-CS and no-shock control paragraphs; Subjects

NBQX alone, 15 mg/kg · Results, Experiment 3: AMPA/nAChR interactions in fear conditioning, Figures 3–4 and captions; Materials and Methods, Subjects, Behavioral procedures: Fear conditioning, Drugs, Statistical analysis

NBQX alone, 30 mg/kg · Results, Experiment 3: AMPA/nAChR interactions in fear conditioning, Figures 3–4 and captions; Materials and Methods, Subjects, Behavioral procedures: Fear conditioning, Drugs, Statistical analysis

NBQX 15 mg/kg plus mecamylamine · Results, Experiment 3: AMPA/nAChR interactions in fear conditioning, Figures 3–4 and captions; Materials and Methods, Subjects, Behavioral procedures: Fear conditioning, Drugs, Statistical analysis

NBQX 30 mg/kg plus mecamylamine · Results, Experiment 3: AMPA/nAChR interactions in fear conditioning, Figures 3–4 and captions; Materials and Methods, Subjects, Behavioral procedures: Fear conditioning, Drugs, Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 118876-58-7
Applications AMPA Receptor Antagonist
Formula C12H8N4O6S
Molecular Weight 336.28
Synonyms FG9202
SMILES
C1=CC2=C3C(=CC(=C2C(=C1)S(=O)(=O)N)[N+](=O)[O-])NC(=O)C(=O)N3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 64 mg/mL (190.31 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Dai WM, Egebjerg J, Lambert JD. Characteristics of AMPA receptor-mediated responses of cultured cortical and spinal cord neurones and their correlation to the expression of glutamate receptor subunits, GluR1-4 British journal of pharmacology (2001). PMID: 11309259 DOI: 10.1038/sj.bjp.0703993 Source material
  2. [2] Gould TJ, Lewis MC. Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning Learning & memory (Cold Spring Harbor, N.Y.) (2005). PMID: 16077017 DOI: 10.1101/lm.89105 Source material

Publications

1 publication citing this product

  1. Huang Li, .et al. , Physiol Behav, 2024, Apr 1:277:114461 PMID: 38215863

Added to your cart

View Cart Checkout
Loading...